
World-first IVF trial reduces risk of babies inheriting diseases
The findings were hailed as a breakthrough which raises hopes that women with mutations in their mitochondrial DNA could one day have children without passing debilitating or deadly diseases on to the children.
One out of every 5,000 births is affected by mitochondrial diseases, which cannot be treated, and include symptoms such as impaired vision, diabetes and muscle wasting.
In 2015, Britain became the first country to approve an in-vitro fertilisation (IVF) technique that uses a small amount of healthy mitochondrial DNA from the egg of a donor -- along with the mother's egg and father's sperm.
Some have called the result of this process "three-parent babies", though researchers have pushed back at this term because only roughly 0.1 percent of the newborn's DNA comes from the donor.
The results of the much-awaited UK trial were published in several papers in the New England Journal of Medicine.
- 'Important reproductive option' -
Out of 22 women to undergo the treatment at the Newcastle Fertility Centre in northeast England, eight babies were born. The four boys and four girls now range from under six months to over two years old.
The amount of mutated mitochondrial DNA -- which causes disease -- was reduced by 95-100 per cent in six of the babies, according to the research.
For the other two newborns, the amount fell by 77-88 per cent, which is below the range that causes disease.
This indicates the technique was "effective in reducing transmission" of diseases between mother and child, one of the studies said.
The eight children are currently healthy, though one had a disturbance of their heart's rhythm which was successfully treated, the researchers said.
Their health will be followed up over the coming years to see if problems arise.
Nils-Goran Larsson, a Swedish reproductive expert not involved in the research, hailed the "breakthrough".
The new technique offers a "very important reproductive option" for families affected by "devastating" mitochondrial diseases, he added.
- Ethical review -
Mitochondrial donation remains controversial and has not been approved in many countries, including the United States and France.
Religious leaders have opposed the procedure because it involves the destruction of human embryos. Other opponents have expressed fears it could pave the way for genetically engineered "designer babies".
An ethical review carried out by the UK's independent Nuffield Council on Bioethics was "instrumental" in conducting the new research, the council's director Danielle Hamm said Wednesday.
Peter Thompson, head of the UK's Human Fertilisation and Embryology Authority which approved the procedure, said only people with a "very high risk" of passing on a mitochondrial disease would be eligible for the treatment.
Ethical concerns have also been raised over the use of mitochondrial donation for infertility in Greece and Ukraine.
French mitochondrial disease specialist Julie Stefann told AFP that "it is a question of the risk-benefit ratio: for a mitochondrial disease, the benefit is obvious".
"In the context of infertility, it has not been proven," she added.
Oxford University reproductive genetics expert Dagan Wells observed that "some scientists will be a little disappointed that so much time and effort has, so far, only led to the birth of eight children".
Among the children being closely monitored are three that showed some signs of what is known as "reversal", which is still little understood.
It is "a phenomenon where the therapy initially succeeds in producing an embryo with very few defective mitochondria, but by the time the child is born the proportion of abnormal mitochondria in its cells has significantly increased," he explained. - Daniel Lawler and Julien Dury / AFP
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Star
5 days ago
- The Star
Quickcheck: Did vanilla flavoring come from beaver glands?
A beaver coming out of the water onto its dam. - Pix by AFP COULD something from a beaver really end up in your dessert? It sounds too crazy to be true, maybe just another piece of viral internet clickbait. But is it true that vanilla flavouring used to be made from something that came out of a beaver? Verdict: TRUE As weird as it sounds, there's a bit of truth to it. The substance in question is called castoreum, a sticky, yellow-brown secretion found in sacs near a beaver's tail. Beavers naturally use it to mark their territory, smearing it on twigs and mud piles. The scent is so musky that humans can easily detect it from a distance. For decades, castoreum was used in perfumes, soaps, and even in some foods - particularly to add vanilla, raspberry, and strawberry flavors. The ancient Greeks even credited it with healing properties. Castoreum contains compounds similar to salicylic acid (like aspirin) and vanillin, the molecule responsible for vanilla's signature taste. But before you panic about your next scoop of ice cream, the use of castoreum in food has almost completely disappeared. Harvesting it isn't easy or pleasant - it involves killing beavers, removing their castor sacs, drying them, and then extracting the flavor using alcohol. It's far from ethical in today's standards. While castoreum is FDA-approved and safe to eat, it was never a widespread food additive - mainly because the process was costly, labor-intensive, and unappealing. Since then, it has become extremely rare, appearing mostly in niche products like certain Swedish liquors. And let's be honest - once people found out where it came from, the "ick" factor alone helped push it out of mainstream use. Today, about 99% of vanilla flavoring comes from synthetic sources, such as lab-made vanillin. It's cheaper, more efficient, and doesn't involve animals at all. So yes, beavers can produce a sweet-smelling substance that was once used to flavor food - but no, it's almost certainly not in anything you're eating today. References: 1. animals/article/beaver-butt- goo-vanilla-flavoring 2. com/smart-news/does-vanilla- flavoring-actually-come-from- beaver-butts-180983288/ 3. en/the-truth-about-artificial- vanilla-extract-and-why-you- should-always-splurge-for-pure 4. health/archive/2013/09/beaver- based-alternative-to-vanilla/ 279811/ 5. plantchemeco/whats-really-in- vanilla/


New Straits Times
6 days ago
- New Straits Times
AstraZeneca beats profit expectations on robust drug sales, US demand
LONDON: AstraZeneca beat second-quarter profit forecasts on robust sales of cancer, heart and kidney disease drugs and strong demand in the US, where it has invested US$50 billion to expand amid tariff threats from President Donald Trump. The beat is a boost for the drugmaker as the wider sector braces for US tariffs on pharmaceutical imports and navigates pricing challenges after Trump's order pushing for prices in the US to fall to what other countries pay. The firm's shares rose around one per cent in early trading on Tuesday. AstraZeneca, the UK's largest-listed company by market value, in April had forecast only a limited impact from potential US tariffs on pharmaceutical imports, and said it would be able to meet its annual outlook if the levies on European imports were similar to those in other industries. A European Union–US trade deal over the weekend will result in a 15 per cent tariff on pharmaceuticals from the region. The Anglo-Swedish drugmaker, which is targeting US$80 billion in annual revenue by 2030, maintained its annual outlook and increased its interim dividend by three per cent. "Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent," CEO Pascal Soriot said in a statement. Sales of AstraZeneca's oncology drugs, which make up nearly half of its revenue and are being weighed down by changes in US Medicare price negotiations, were up 18 per cent at US$6.31 billion at constant currency rates for the three-month period ended June 30. Analysts at Jefferies said sales of key cancer drugs such as Tagrisso, Lynparza, Calquence, Truqap and Imfinzi were ahead of expectations. Total revenue grew 11 per cent to US$14.46 billion, with core earnings of US$2.17 per share, and double-digit growth in the US, which makes up more than 40 per cent of sales. That compares with analysts' expectations of US$14.15 billion and US$2.16, respectively, according to a company-provided consensus. AstraZeneca, which is hoping to move on from scandals in its second-biggest market, China, where it also faces minor fines related to cancer drugs, said it was also fighting several patent challenges from an individual against Tagrisso.


The Star
24-07-2025
- The Star
More British babies born via IVF, showing changing landscape of fertility care
IVF births in Britain have increased from 1.3% in 2000 to 3.1% in 2023. Photo: Freepik The equivalent of almost one child in every classroom in Britain is now born as a result of in-vitro fertilisation or IVF fertility treatment, new figures suggest. Almost 21,000 babies were born from IVF in 2023, compared to 8,700 in 2000, the Human Fertilisation and Embryology Authority (HFEA) said. The authors of the fertility regulator's latest report wrote: "IVF births are making up a higher proportion of all British births over time, increasing from 1.3% in 2000 to 3.1% in 2023. "This means around one in 32 British births in 2023 were via IVF – roughly one child in every classroom – compared to one in 43 in 2013.' The HFEA said that its latest figures show the "changing landscape' of fertility care in Britain. Overall, 52,400 patients had ,ore than 77,500 in vitro fertilisation (IVF) cycles at British fertility clinics in 2023. Some 11% of births to women aged 40-44 were a result of IVF, increasing from 4% in 2000 and accounting for 0.5% of all births, HFEA said. The data also reveal a rise in the proportion of women freezing their eggs – a rise from 4,700 in 2022 to 6,900 in 2023 – but the HFEA said that the number of patients using their stored frozen eggs in treatment remains "low.' Meanwhile the HFEA also said that in 2023, around 820 babies were born following donor insemination (DI) treatment. The figures also show a reduction in the number of IVF treatments funded by the NHS. The proportion of NHS-funded IVF cycles declined from 35% in 2019 to 27% in 2023. Racial disparities The HFEA also raised concerns about racial disparities in IVF. It said that in recent years, Asian and Black patients have had lower birth rates compared to white patients and those from a mixed ethnic background. Julia Chain, chairwoman of the HFEA, said: "IVF is helping more people have babies including patients of different ages and family types. "One in 32 of all British births are from IVF and 11% of all UK births are to women aged 40-44 who had IVF. "These findings highlight the changing landscape of the fertility sector and how it could develop in the years to come. "However, we are very concerned to see that Black and Asian patients continue to have lower IVF birth rates compared to other patient groups, and our recent survey found that Asian and Black patients are less likely to report being satisfied with their fertility treatment.' Data from the Office for National Statistics show that the fertility rate in England and Wales in 2023 was 1.44 children per woman – the lowest level on record. Commenting on the HFEA data, a spokesperson from the fertility charity Fertility Network UK said: "This important report from the HFEA reflects how essential fertility treatment has become for growing families and underlines not just the scientific advances in fertility care, but also the profound social impact of helping people realise their dreams of parenthood. "Delays in accessing treatment – whether due to long GP referral times or inconsistent NHS funding – can have a devastating emotional and biological impact. We call for fair and timely access to fertility services for all, wherever they live and whatever their background.' – dpa